Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald S Levy

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Ophthalmology|July 4, 2006
IOP variationDonald S Levy
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2025
Berotralstat, the first oral prophylaxis for hereditary angioedema in children aged 2 to 12 years: The kids are alright!Donald S Levy
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|June 28, 2021
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapyJohn Anderson, Donald S Levy, William Lumry, et al.
Allergy and Asthma Proceedings|September 17, 2025
Quality of life and burden of disease in patients with hereditary angioedema and their caregiversDonald S Levy, Fernanda I Nagase, Antoinette Cheung, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|February 12, 2020
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trialDonald S Levy, Henriette Farkas, Marc A Riedl, et al.
Allergy and Asthma Proceedings|December 27, 2023
An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapyWilliam R Lumry, Jonathan A Bernstein, Henry H Li, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Ophthalmology|July 4, 2006
IOP variationDonald S Levy
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2025
Berotralstat, the first oral prophylaxis for hereditary angioedema in children aged 2 to 12 years: The kids are alright!Donald S Levy
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|June 28, 2021
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapyJohn Anderson, Donald S Levy, William Lumry, et al.
Allergy and Asthma Proceedings|September 17, 2025
Quality of life and burden of disease in patients with hereditary angioedema and their caregiversDonald S Levy, Fernanda I Nagase, Antoinette Cheung, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|February 12, 2020
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trialDonald S Levy, Henriette Farkas, Marc A Riedl, et al.
Allergy and Asthma Proceedings|December 27, 2023
An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapyWilliam R Lumry, Jonathan A Bernstein, Henry H Li, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 2